E
Elena Musat
Researcher at European Organisation for Research and Treatment of Cancer
Publications - 18
Citations - 2668
Elena Musat is an academic researcher from European Organisation for Research and Treatment of Cancer. The author has contributed to research in topics: Prostate cancer & Radiation therapy. The author has an hindex of 11, co-authored 15 publications receiving 2480 citations. Previous affiliations of Elena Musat include Institut Gustave Roussy.
Papers
More filters
Journal ArticleDOI
Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer
Berend J. Slotman,Corinne Faivre-Finn,G.W.P.M. Kramer,E.M. Rankin,Michael Snee,Matthew Hatton,Pieter E. Postmus,Laurence Collette,Elena Musat,Suresh Senan +9 more
TL;DR: Prophylactic cranial irradiation reduces the incidence of symptomatic brain metastases and prolongs disease-free and overall survival and did not have a clinically significant effect on global health status.
Journal ArticleDOI
Duration of androgen suppression in the treatment of prostate cancer.
Michel Bolla,Theodorus M. de Reijke,Geertjan van Tienhoven,Alphonsus C.M. van den Bergh,Jorg R. Oddens,Philip Poortmans,Eliahu Gez,Paul Kil,Atif Akdas,Guy Soete,Oleg B. Kariakine,Elsbietha M. van der Steen-Banasik,Elena Musat,Marianne Pierart,Murielle Mauer,Laurence Collette +15 more
TL;DR: The combination of radiotherapy plus 6 months of androgen suppression provides inferior survival as compared with radiotherapyplus 3 years of androgens suppression in the treatment of locally advanced prostate cancer.
Journal ArticleDOI
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.
Alexander M.M. Eggermont,Stefan Suciu,Mario Santinami,Alessandro Testori,Wim H. J. Kruit,Jeremy Marsden,Cornelis J. A. Punt,François Sales,Martin Gore,Rona M. MacKie,Zvonko Kusić,Reinhard Dummer,Axel Hauschild,Elena Musat,Alain Spatz,Ulrich Keilholz +15 more
TL;DR: Adjuvant pegylated interferon alfa-2b for stage III melanoma has a significant, sustained effect on recurrence-free survival.
Journal Article
EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.
Alexander M.M. Eggermont,Stefan Suciu,Mario Santinami,Alessandro Testori,Wim H. J. Kruit,J. Marsden,Cornelis J. A. Punt,François Sales,M. E. Gore,R.M. Mackie,Zvonko Kusić,Reinhard Dummer,Axel Hauschild,Paul Lorigan,Elena Musat,Alain Spatz,Ulrich Keilholz +16 more
Journal ArticleDOI
Long-Term Protective Effect of Mature DC-LAMP+ Dendritic Cell Accumulation in Sentinel Lymph Nodes Containing Micrometastatic Melanoma
Bruce Elliott,Richard A. Scolyer,Stefan Suciu,Serge Lebecque,Donata Rimoldi,Oliver Gugerli,Elena Musat,Raghwa Sharma,Danielle Liénard,Ulrich Keilholz,Alessandro Testori,Alexander M.M. Eggermont,Rona M. MacKie,Caroline Robert,Martin G. Cook,John F. Thompson,Eric Angevin,Alain Spatz +17 more
TL;DR: In this paper, the prognostic importance of the maximal density of mature dendritic cells (DCs) in sentinel lymph nodes (SLN) draining regressing melanomas was investigated.